在2型和非2型喘中出现的新兴生物标
Andrea E Davis1,2, Sarah Rhoads2, Michael E Wechsler2
1Division of Pulmonary, Allergy and Critical Care Medicine, the Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.
Current opinion in pulmonary medicine
|February 24, 2026
概括
新型疗法旨在通过针对新的途径和使用先进的药物输送来实现严重喘的缓解. 目前的生物药物可以改善症状,但往往无法完全缓解由于喘的症状.
科学领域:
- 肺病学和呼吸系统医学
- 药理学和药物开发领域
背景情况:
- 严重的喘仍然是全球主要的健康挑战,对发病率和死亡率做出了重大贡献.
- 尽管在过去二十年里喘管理方面取得了进展,但在严重病例中实现完全缓解仍然是许多患者难以捉摸的.
研究的目的:
- 审查正在研究的针对严重喘管理的新型治疗药物和策略.
- 探索新的目标和机制,旨在使严重喘患者能够实现缓解.
主要方法:
- 对当前和新兴的严重喘药物开发策略的审查.
- 确定新的治疗点,包括布鲁顿氨酸激酶,OX-40配体,Janus激酶,CC-化学因子受体4 (CCR4) 和GATA-3.
- 分析新的方法,如超长效应配方和组合生物疗法.
主要成果:
- 目前的喘生物学药物显著改善了症状控制,生活质量,并减少了许多患者的全身类固醇使用.
- 新型药物开发策略包括超长效机制,组合生物药物,口服疗法和针对新途径.
- 重症喘治疗的新兴点包括布鲁顿氨酸激酶,OX-40配体,Janus激酶,CCR4和GATA-3.
结论:
- 虽然现有的生物药物提供了巨大的好处,但由于解决喘复杂病理生理学的局限性,它们往往无法诱导缓解.
- 目前正在积极研究一系列新的治疗机制和点,以克服当前治疗的局限性.
- 未来的研究重点是创新方法,以实现持续缓解和改善严重喘患者的长期结果.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:26Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51